Limited EvidencePeptide

Semax

The Russian nootropic

Neuroprotective Peptide (ACTH fragment analog)

Last updated: August 2026

Evidence Level: Limited Evidence

Mostly animal data or anecdotal reports, theoretical basis

Regulatory Status: Registered in Russia since 1994 for cerebrovascular and cognitive indications. Not approved in the US or EU. On July 24, 2026 an FDA advisory committee voted to recommend adding it to the permitted 503A list; that vote is advisory and non-binding.

Semax is a synthetic peptide derived from ACTH, modified so it keeps the brain effects without the hormonal ones. It has been a registered medication in Russia since 1994, used mainly for stroke recovery and cognitive conditions. It has never been tested in a randomized controlled trial meeting Western regulatory standards.

How It Works

ACTH is the hormone that tells your adrenal glands to make cortisol. It turns out that a specific fragment of ACTH, amino acids 4 through 10, has effects on the brain that are separate from the hormonal signaling. Russian researchers took that fragment, attached a short stabilizing sequence, and produced Semax: something that acts on the brain without triggering a cortisol response.

BDNF is the headline mechanism. Semax has been reported to substantially increase brain-derived neurotrophic factor and its receptor in the hippocampus, the region central to memory formation. BDNF supports the survival of existing neurons and the growth of new connections, and low BDNF is associated with depression and cognitive decline. If Semax raises BDNF meaningfully in humans, that is a real mechanism for cognitive and mood effects.

Other reported effects. It appears to modulate dopamine and serotonin systems, to have neuroprotective effects during oxygen deprivation (the basis for the stroke indication), and to influence the activity of enzymes that break down neuropeptides.

Why the stroke indication exists. In Russia, Semax is used in acute ischemic stroke, given intranasally in the early hours and days. The theory is neuroprotection: limiting damage to brain tissue around the core of the stroke while blood flow is compromised.

The evidence problem, stated plainly. The most rigorous published human study of Semax in stroke enrolled 110 post-stroke patients on 6,000mcg per day intranasally and reported improvements on the Barthel index and MRC motor scale. That trial was not randomized, had no placebo control, and was conducted by a single Russian research group.

Stroke recovery is exactly the setting where uncontrolled studies mislead. People recover from strokes on their own, substantially and variably, over exactly the window these studies measure. Without a control group you cannot tell recovery from treatment. This is not a technicality; the history of stroke medicine is full of neuroprotective agents that looked wonderful in uncontrolled studies and did nothing in randomized trials.

The July 2026 development. An FDA advisory committee voted to recommend adding Semax to the permitted 503A compounding list, for selected neurologic uses. That vote was advisory, was reported as narrow, and does not change Semax's legal status without subsequent FDA rulemaking.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Cognitive functionVery Low
Cognitive functionPreclinical

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Cognitive functionVery Low certainty

Improves functional recovery after ischemic stroke.

Population: Adults recovering from ischemic stroke

Why this rating

The strongest published human evidence is a 110-patient study that was neither randomized nor placebo-controlled, conducted by a single research group. Stroke recovery involves substantial and highly variable spontaneous improvement over exactly the period these studies measure, so without a control group the observed improvement cannot be attributed to the drug. Stroke neuroprotection is a field littered with agents that looked effective in uncontrolled studies and failed in randomized trials.

GRADE downgrade factors applied

Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).
Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.
Publication bias: Suspicion that negative or null results were not published, inflating apparent effect.

Supporting studies

Semax in post-stroke rehabilitationObservational Study
n=110
Improved Barthel index and MRC motor scale scores in an uncontrolled study.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Cognitive functionPreclinical certainty

Improves memory, focus, or cognitive performance in healthy adults.

Population: Healthy adults. This is the population it is most heavily marketed to in the West.

Why this rating

The case rests on animal studies showing increased BDNF and neuroprotection, plus extrapolation from clinical use in neurological disease. We could not identify a controlled trial of Semax in healthy adults with cognitive performance as a primary outcome. Nootropic effects are also among the most placebo-susceptible outcomes in medicine, which makes uncontrolled reports close to uninformative.

Supporting studies

Semax effects on BDNF expression in rat hippocampusAnimal Study
Increased BDNF and TrkB receptor expression in animal models.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

A registered medication in Russia for more than 30 years, so it cleared a real regulatory process somewhere
Reported to substantially increase BDNF, a well-validated target for cognition and mood
Intranasal administration allows more direct delivery toward the brain, with no injection needed
No cortisol response despite being derived from ACTH, since the hormonal portion of the molecule was left out
Generally reported as well tolerated across decades of Russian clinical use
An FDA advisory committee voted in July 2026 to recommend it for the permitted compounding list

Risks & Considerations

No randomized, placebo-controlled trial meeting Western regulatory standards has been published for any indication
The most cited stroke study was not randomized and had no placebo control, in a condition where spontaneous recovery is the norm
Evidence is concentrated in Russian-language literature from a limited number of affiliated research groups
Not approved in the US or EU, so supply here is unregulated with unverified purity and dose
Marketed for cognitive enhancement in healthy people, a use with essentially no controlled evidence
Long-term safety data outside Russian clinical experience does not exist
The July 2026 advisory vote is not approval and does not change its legal status today

Dosing Information

Russian clinical practice has established dosing for its registered indications. Nootropic dosing in the West is community convention.

•Russian stroke protocols have used doses up to 6,000mcg per day intranasally in the acute setting
•Community nootropic use is typically far lower, in the range of 300 to 900mcg daily intranasally
•Sold in two forms: standard Semax and N-acetyl Semax, the latter claimed to be longer-acting, a claim without published human comparison
•Courses of 10 to 14 days are the norm in Russian practice rather than continuous use
•Frequently stacked with Selank in community protocols, a combination with no trial evidence

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

1Separate the two use cases. The stroke indication has decades of Russian clinical use behind it; the healthy-brain nootropic use has almost nothing
2If you are considering this after a stroke, that is a neurologist conversation, and the approved stroke treatments come first
3Nasal spray is the form with the clinical track record. Injectable preparations are a Western improvisation
4The N-acetyl version is sold at a premium on the basis of a longer half-life that has not been demonstrated in a published human comparison
5Cognitive self-assessment is unreliable. If you try it, use an objective test you can repeat rather than how sharp you feel
6Watch the FDA rulemaking following the July 2026 advisory vote if quality control matters to you

Key Research

Semax in post-stroke rehabilitation

Russian-language clinical literature

Post-stroke patients receiving 6,000mcg per day intranasally showed improved Barthel index and MRC motor scale scores. The study was not randomized, had no placebo control, and came from a single research group.

Semax effects on BDNF expression

Preclinical studies

Semax increased BDNF and its TrkB receptor expression in the rat hippocampus, and showed neuroprotective effects in models of cerebral ischemia.

FDA Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026

FDA advisory committee proceedings, 2026

The committee voted to recommend Semax for the 503A bulk drug substances list for selected neurologic uses. The vote was reported as narrow, is advisory, and does not change Semax's legal status without FDA rulemaking.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All Treatments Find Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has limited human evidence.

Frequently Asked Questions

What is Semax?

Semax is a synthetic peptide based on amino acids 4 through 10 of ACTH, with a stabilizing sequence added. The modification keeps the brain-active portion while removing the part that would trigger cortisol release. It has been a registered medication in Russia since 1994, used mainly for stroke recovery and cognitive conditions, and is taken as a nasal spray.

Does Semax work for cognitive enhancement?

There is no controlled trial evidence in healthy people. The mechanism is interesting: animal studies show Semax substantially increases BDNF, which supports neuron survival and growth. But no controlled human trial has tested Semax for cognitive performance in healthy adults, and cognitive enhancement is one of the most placebo-responsive outcomes there is. The Russian clinical evidence is for neurological disease, not for making a healthy brain sharper.

Is Semax approved by the FDA?

No. It is registered in Russia but not approved in the US or EU. It was placed in FDA Category 2 in 2023. On July 24, 2026 an FDA advisory committee voted to recommend adding Semax to the permitted 503A compounding list for selected neurologic uses. That vote is advisory and non-binding, and changing its status requires FDA rulemaking that typically takes 12 to 24 months.

How good is the evidence for Semax in stroke?

Weaker than its 30 years of clinical use suggests. The most rigorous published study enrolled 110 post-stroke patients and reported improvement on functional scales, but it was not randomized and had no placebo group. That is a serious problem in stroke, where people recover substantially on their own over the same window. Many neuroprotective agents have looked good in uncontrolled stroke studies and then failed randomized trials.

What is the difference between Semax and N-acetyl Semax?

N-acetyl Semax has an acetyl group added, which vendors claim makes it more stable and longer-acting. It is generally sold at a premium for that reason. We could not identify a published human study directly comparing the two forms, so treat the longer-acting claim as a manufacturer assertion rather than a demonstrated difference.

What is the difference between Semax and Selank?

Both are Russian-registered intranasal peptides with the same underlying evidence problem, but they come from different places and are used differently. Semax derives from ACTH and is used for stroke and cognitive indications. Selank derives from tuftsin, an antibody fragment, and is used for anxiety. People often stack them, a combination that has never been studied.

Are there side effects from Semax?

It is generally reported as well tolerated across decades of Russian clinical use, with nasal irritation the most commonly mentioned effect. The honest limitation is that systematic side effect data outside Russian clinical experience does not exist, and long-term safety has not been studied under modern standards.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Sharper Mind Guide

Compare Semax

Semax vs Selank

Different jobs, and the same evidence problem

Related Peptides

SelankAnxiolytic Peptide (tuftsin analog)

TesamorelinGrowth Hormone-Releasing Hormone Analog